Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Olivier Hanon
Multimodal data-driven clustering analysis of heart failure patients identifies two distinct patterns of heart failure with preserved ejection fraction: Results from the PACIFIC-PRESERVED study
Abstract Heart failure with preserved ejection fraction (HFpEF) accounts for over half of heart failure cases but remains poorly defined due to its clinical heterogeneity. In the prospective PACIFIC-Preserved cohort (NCT04189029, n = 155), we applied multimodal deep phenotyping, including high-throughput proteomics, and unsupervised machine learning to identify biologically distinct HFpEF subgroups.
Beyond amyloid and tau: synaptic and neurodegenerative biomarkers shape MCI progression
Abstract Accurate prediction of which patients with mild cognitive impairment (MCI) will progress to dementia remains a major challenge. Current biomarkers detect amyloid pathology with high accuracy but offer limited prognostic value for disease progression. We conducted a prospective analysis in the multicentre BALTAZAR cohort, all diagnosed with MCI at baseline and followed for 3 years.
Machine learning in Alzheimer’s disease genetics
|
Scientists just discovered a secret code hidden in your DNA What scientists once dismissed as “junk” DNA may actually be some of the most powerful code in our genome. A new international study reveals that …
By Matthew Bracher-Smith, Federico Melograna, Brittany S. Ulm, Céline Bellenguez, Benjamin Grenier-Boley, Diane Duroux, Peter A Holmans, Betty M. Tijms, Marc Hulsman, Itziar de Rojas, Rafael Campos-Martin, Fahri Küçükali, Oliver Peters, Anja Schneider, Martin Dichgans, Dan Rujescu, Norbert Scherbaum, Jürgen Deckert, Steffi G. Riedel-Heller, Lucrezia Hausner, Laura Molina-Porcel, Emrah Düzel, Timo Grimmer, Jens Wiltfang, Stefanie Heilmann-Heimbach, Susanne Moebus, Thomas Tegos, Nikolaos Scarmeas, Oriol Dols-Icardo, Fermín Moreno, Jordi Pérez-Tur, Maria Bullido, Raquel Sánchez-Valle, Victoria Alvarez, Mercè Boada, Pablo García-González, Raquel Puerta, Pablo Mir, Luis M. Real, Gerard Piñol-Ripoll, Jose María García-Alberca, Eloy Rodriguez-Rodriguez, Hilkka Soininen, Sami Heikkinen, Alexandre de Mendonça, Latchezar Traykov, Jakub Hort, Martin Vyhnálek, Nicolai Sandau, Jesper Qvist Thomassen, Henne Holstege, Inez H.G.B. Ramakers, Frans R Verhey, Philip Scheltens, Caroline Graff, Goran Papenberg, Vilmantas Giedraitis, Julie Williams, Philippe Amouyel, Anne Boland, Jean-Francois Deleuze, Gaël Nicolas, Carole Dufouil, Florence Pasquier, Olivier Hanon, Stéphanie Debette, Edna Grünblatt, Julius Popp, Roberta Ghidoni, Daniela Galimberti, Beatrice Arosio, Patrizia Mecocci, Vincenzo Solfrizzi, Lucilla Parnetti, Alessio Squassina, Lucio Tremolizzo, Barbara Borroni, Michael Wagner, Benedetta Nacmias, Davide Seripa, Innocenzo Rainero, Antonio Daniele, Fabrizio Piras, Giacomina Rossi, Frank Jessen, Patrick Kehoe, Tsolaki Magda, Pascual Sanchez-Juan, Kristel Sleegers, Martin Ingelsson, Mikko Hiltunen, Rebecca Sims, Ole A. Andreassen, Agustín Ruiz, Alfredo M. Ramirez, Alfredo Ramírez, Ruth Frikke-Schmidt, Najaf Amin, Gennady V Roshchupkin, Jean-Charles Lambert, Kristel Van Steen, Cornelia van Duijn, Valentina Escott-Price, Alejo J. Nevado, Atahualpa Castillo, Shima Mehrabian, John van Swieten, Marco Spallazzi, Carlo Masullo
|
Flipboard
Enhanced influenza vaccination for older adults in Europe: a review of the current situation and expert recommendations for the future
ABSTRACT Introduction Influenza causes considerable morbidity and mortality in Europe, particularly among older adults due to comorbidities, as well as immunosenescence and inflammaging, which contribute to a diminished immune response. Vaccination remains the most effective way to prevent poor outcomes; however, uptake is suboptimal and many countries recommend standard vaccines despite evidence supporting better protection with enhanced (adjuvanted and high-dose) vaccines.
Venous thromboembolism in patients aged ≥90 years: Trends in clinical features, treatment, and outcomes-RIETE registry
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest relevant to the study reported. Supporting Information Filename Description jgs19306-sup-0001-Appendix.pdfPDF document, 925.9 KB Supplementary Table S1. Temporal trends in initial PE presentation (limited to patients initially presenting with PE). Over time, the clinical severity of diagnosed PEs decreased.
Anticoagulation and venous thromboembolism in patients aged 90 years and older: Data from the RIETE registry
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest relevant to the study reported. Supporting Information Filename Description jgs18626-sup-0001-TablesS1-S3,FigureS1.pdfPDF document, 303.1 KB Supplementary Table S1. Treatment strategies during the first 3 months of anticoagulation Supplementary Table S2. Treatment strategies and outcomes during the first 3 months of anticoagulation specifically in patients aged ≥100 years. Supplementary Table S3.
Optimización de los tratamientos de la insuficiencia cardiaca con fracción de eyección reducida en la práctica diaria: propuesta de un grupo de expertos
Nicolas Girerd [1] ; Christophe Leclercq [2] ; Olivier Hanon [3] ; Antoni Bayés Genís [4] ; James L.
Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation
Arrhythmias and sudden death Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation Olivier Hanon1, http://orcid.org/0000-0001-6770-0720Jean-Sébastien Vidal1, George Pisica-Donose1,2, Galdric Orvoën1, Jean-Philippe David3, Edouard Chaussade1, Laure Caillard1, Laura W de Jong4, Nicolas Boulloche5, Ulric Vinsonneau6, Stéphane Bouée7, Pierre Krolak-Salmon8, Laurent Fauchier9, Pierre Jouanny10, Guillaume Sacco11, Fabienne...
Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation
Arrhythmias and sudden death Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation Olivier Hanon1, http://orcid.org/0000-0001-6770-0720Jean-Sébastien Vidal1, George Pisica-Donose1,2, Galdric Orvoën1, Jean-Philippe David3, Edouard Chaussade1, Laure Caillard1, Laura W de Jong4, Nicolas Boulloche5, Ulric Vinsonneau6, Stéphane Bouée7, Pierre Krolak-Salmon8, Laurent Fauchier9, Pierre Jouanny10, Guillaume Sacco11, Fabienne...
The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly
Atrial fibrillation (AF) is the most common arrhythmia and its prevalence increases with age. Age also increases the risk of thromboembolism related to AF. As a result, elderly patients are at increased risk of AF-related stroke compared to younger patients. Age, however, also increases the risk of bleeding, including that of intracranial haemorrhage, an important cause of death and disability.
Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers
In our study, plasma Aβ1–42 and Aβ1–40 levels were lower in AD than in aMCI than in naMCI participants. Interestingly, plasma Aβ1–42 correlated with the three CSF biomarkers in all MCI but only with CSF Aβ42 in AD. A correlation was also found between plasma Aβ1–42 and MMSE in AD. In aMCI participants, plasma Aβ1–42 correlated with CSF tau and p-Tau.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Olivier
Contact Olivier, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack